Overview:

Are you a Genitourinary Oncologist seeking an academic-focused opportunity in Louisiana? Tulane Cancer Center is an emerging NCI-designated comprehensive cancer center whose purposes are the treatment and control of cancer, the advancement of biomedical knowledge through laboratory and clinical research, and the training of physicians, scientists, and other healthcare workers. With a rich history dating back to the 19th century, our School of Medicine prides itself on its legacy of excellence and innovation. We empower our physicians to become leaders in their field by collaborating with bench researchers, heading clinical trials, and publishing as primary authors for translational clinical trial research.

About the Role:

As a GU Oncologist at our institution, you'll play a leading role in our academic-focused Hematology/Oncology department:

• Mentor fellows, residents, and medical students, fostering their growth and development through research-driven multi-disciplinary care. 
• Lead clinical trial research initiatives, collaborating with bench researchers and publishing groundbreaking findings as primary authors.
• 50% protected time (minimum) for incoming faculty 
• Primarily manage prostate cancer cases
• Make a direct impact in combating prostate cancer, which represents 14.4% of all new cancer cases in Louisiana

Research and Clinical Trials:

This is a unique opportunity to spearhead innovative research, directly impacting the fight against cancer and establishing yourself as a leader in the field. 

Trial 1: Pancreatic Cancer (Phase II): 

• This Phase II trial evaluates the efficacy of adding olaparib, a DNA repair inhibitor, to the treatment regimen of pancreatic cancer patients with BRCA1, BRCA2, or PALB2 mutations who have had surgery. The study aims to determine if inhibiting DNA repair can help eradicate cancer cells in this specific patient group.

Trial 2: Prostate Cancer (Phase III): 

• This Phase III trial examines if adding apalutamide to standard post-surgery treatment (radiation and hormone therapy) enhances outcomes in patients with lymph node positive prostate cancer. Apalutamide inhibits the binding of androgens to cancer cells, aiming to decelerate their growth and dissemination, potentially improving disease control and extending progression-free survival.

Trial 3: Kidney Cancer (Phase III): 

• This trial evaluates whether combining surgery with standard immunotherapy drugs offers more benefits than using the drug combination alone in treating metastatic kidney can